Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is
highly expressed in skeletal muscle, was first described in 1997. It has been known that loss …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

Myostatin, a member of the TGF-β family, has been identified as a powerful inhibitor of
muscle growth. Absence or blockade of myostatin induces massive skeletal muscle …

A decade has passed since myostatin was first identified as a negative regulator of muscle
growth. Since then, studies in both humans and animals have demonstrated that decreasing …

Glucocorticoids mediate muscle atrophy in many catabolic states. Myostatin expression, a
negative regulator of muscle growth, is increased by glucocorticoids and myostatin …

Myostatin is a strong inhibitor of skeletal muscle growth. The purpose of this study was to
investigate myostatin expression profiles during denervation‐induced muscle atrophy in …

Inhibition of myostatin signalling or its biological activity has recently emerged as a potential
remedial approach against muscle wasting and degenerative diseases such as muscular …

Myostatin is a negative regulator of muscle growth and fiber size. Changes in myostatin
expression might contribute to changes in muscle mass associated with various conditions …

Background The treatments currently approved for Duchenne muscular dystrophy (DMD), a
progressive skeletal muscle wasting disease, address the needs of only a small proportion …

Myostatin deficiency leads to both an increased rate of protein synthesis and skeletal muscle
hypertrophy. However, the mechanisms involved in mediating these effects are not yet fully …